Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Capricor Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
FAQ
- What is Capricor Therapeutics's EBIT?
- Capricor Therapeutics (CAPR) reported EBIT of -$36.77M in Q1 2026.
- How has Capricor Therapeutics's EBIT changed year-over-year?
- Capricor Therapeutics's EBIT decreased by 47.2% year-over-year, from -$24.98M to -$36.77M.
- What is the long-term trend for Capricor Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Capricor Therapeutics's EBIT has grown at a 50.8% compound annual growth rate (CAGR), from -$20.94M to -$108.14M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Capricor Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude